# US 8,278,282 B2 · Nucleoside analogs for treatment of viral infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,282 B2
- Document ID: US8278282B2
- Status: Granted
- Kind: B2
- Application number: 12/526,079
- Filed: 2008-02-07
- Published: 2010-09-09
- Granted: 2012-10-02
- Earliest claimed: 2007-02-09
- Assignees: Novartis AG
- Inventors: Zheng Yin; Jeyaraj Duraiswamy; Yen Liang Chen
- Web page: https://patentgrep.com/patent/US8278282B2

## CPC

- C07H 19/23: Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to novel compounds that have various medicinal applications, e.g. for the treatment and/or prevention of viral infections.

## Claims

### Claim 1

A compound of formula (I), or a pharmaceutically acceptable salt or prodrug thereof:
wherein:
X is CH or CR4;
R1 is halogen, NR5R6 or OR7;
R2 is H, halogen, or NR5R6;
R3 is H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl or heteroaryl, each of which is optionally substituted with one or more substituents;
R4 is alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, halogen, cyano, nitro, hydroxy, alkoxy, alkylthio, amino, alkylamino, carboxy, carboxamide or alkyloxycarbonyl, each of which is optionally substituted with one or more substituents;
R5 and R6 are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, amino, alkylamino, arylamino, hydroxy, alkoxy, arylcarbonyl and alkylcarbonyl, each of which is optionally substituted with one or more substituents; and
R7 is H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, alkylcarbonyl or arylcarbonyl, each of which is optionally substituted with one or more substituents.

### Claim 2 (depends on 1)

The compound as claimed in claim 1 which is a compound of formula (II), or a pharmaceutically acceptable salt or prodrug thereof:
wherein:
X is CH or CR4;
R1 is halogen, NR5R6 or OR7;
R2 is H, halogen, or NR5R6;
R3 is H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl or heteroaryl, each of which is optionally substituted with one or more substituents;
R4 is alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, halogen, cyano, nitro, hydroxy, alkoxy, alkylthio, amino, alkylamino, carboxy, carboxamide or alkyloxycarbonyl, each of which is optionally substituted with one or more substituents;
R5 and R6 are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, amino, alkylamino, arylamino, hydroxy, alkoxy, arylcarbonyl and alkylcarbonyl, each of which is optionally substituted with one or more substituents; and
R7 is H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, alkylcarbonyl or arylcarbonyl, each of which is optionally substituted with one or more substituents.

### Claim 3

A compound selected from the group consisting of:

### Claim 4

(2R,3R,4R,5R)-2-(4-amino-pyrrolo[2,3-d]pyrimidin-7-yl)-3-ethynyl-5-hydroxymethyl-tetrahydrofuran-3,4-diol.

### Claim 5

(2R,3R,4R,5R)-2-(4-amino-5-ethynyl-pyrrolo[2,3-d]pyrimidin-7-yl)-3-ethynyl-5-hydroxymethyl-tetrahydrofuran-3,4-diol or (2R,3R,4R,5R)-2-(4-amino-5-fluoro-pyrrolo[2,3-d]pyrimidin-7-yl)-3-ethynyl-5-hydroxymethyl-tetrahydrofuran-3,4-diol.

### Claim 6 (depends on 1)

A pharmaceutical composition comprising a compound as claimed in claim 1, or a pharmaceutically acceptable salt or prodrug thereof, in combination with a pharmaceutically acceptable excipient, diluent or carrier.

### Claim 7 (depends on 1)

A method of treating a disease caused by infection by a virus selected from the group consisting of dengue virus, yellow fever virus, West Nile virus, Japanese encephalitis virus, tick-borne encephalitis, Kuhjin virus, Murray Valley encephalitis virus, St. Louis encephalitis virus, Omsk hemorrhagic fever virus, bovine viral diarrhea virus, Zika virus, and hepatitis C virus, comprising administering to a patient in need thereof an effective amount of a compound of claim 1.

### Claim 8 (depends on 7)

The method of claim 7 wherein the viral infection is caused by dengue virus.
